Physician profile
David Rossi
NPI 1720283807
$2,539.35
in general payments reported to CMS, 2019-2025
22 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $173 · 2021: $98.62 · 2022: $415 · 2023: $790 · 2024: $614 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.79 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $641.66 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $402.18 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $290.45 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $279.47 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $263.80 | 2022-2024 | Vraylar |
| Pfizer INC. | $97.56 | 2019-2020 | |
| Abbott Laboratories | $92.60 | 2021-2022 | |
| Alkermes, INC. | $79.65 | 2023 | Lybalvi |
| Merck Sharp & Dohme LLC | $74.60 | 2023-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $67.04 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $51.22 | 2019-2020 | |
| Esperion Therapeutics, INC. | $49.57 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $21.20 | 2024 | Eliquis |
| Genentech USA, INC. | $18.54 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.40 | 2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.09 | 2019 | |
| Smith+Nephew, INC. | $14.82 | 2020 | |
| Sanofi Pasteur INC. | $14.49 | 2019 | |
| Cranial Technologies, INC | $13.67 | 2024 | Doc Band |
| Sunovion Pharmaceuticals INC. | $12.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.89 | 2020 | |
| Eisai INC. | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.